http://www.lsis.com/goto/r116/rss 2010-06-23T11:11:13+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v116/%3B%97f%FD%1D%7E%7D%7D ChemMedChem. |-| Gatfield J, Brisbare-Roch C, Jenck F, Boss C. |-| Drug Discovery Biology, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, 4123 Allschwil/BL (Switzerland). text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v116/%3B%97f%FD%11%7E%7F%7D DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f8d776/global_top_10_biot) has announced the addition of the "Global Top 10 Biotechnology Companies Industry, Financial and SWOT Analysis" report to their offering. Global Top 10 Biotechnology Companies Industry, Financial and SWOT Analysis Introduction This report analyzes the global biotechnology market in terms of market size (reflects revenues of companies within this industry from product sales, licensing fees, royalties and research funding), key drivers and resistors, trends and competitive positioning. It includes profiles of the top ten companies in the industry along with 5-year financial (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v116/%3B%97g%F7%10%7Dx%7D DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/1e827b/new_product_planni) has announced the addition of the "New Product Planning: Role and Activities for Medical Marketing" report to their offering. New Product Planning: Role and Activities for Medical Marketing Leading pharmaceutical and biotech companies are increasingly under pressure to deliver effective new products in shorter time frames while minimizing development costs. The structure, activities, and resources of New Product Planning (NPP) groups are critical to focusing new product development and optimizing product portfolios. This benchmarking study examines the role and impact of NPP (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v116/%3B%97g%F7%14%7Fyy BERLIN-(BUSINESS WIRE)-NOXXON Pharma AG (NOXXON), a company focused on the development of mirror image oligonucleotide therapeutics called Spiegelmers, announced today the successful closing of a ¬33 million Series D round of financing. The round was led by new investor, NGN Capital, and joined by existing investors TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin GmbH, Dow Venture Capital, FCP OP MEDICAL BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, the Dieckell Group, and others. The funds raised will be used primarily for the ongoing clinical and pre-clinical development of NOXXON s lead (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v116/%3B%97g%F9%14tx%7E SCOTTSDALE, Ariz.-(BUSINESS WIRE)-The National Council for Prescription Drug Programs (NCPDP) announced today the second consecutive year of record-breaking attendance at its Annual Technology and Business Conference. The 2010 conference garnered the attention of stakeholders from across the healthcare industry pharmacy benefit managers, retail and independent pharmacies, software vendors, manufacturers, wholesale distributors, database management organizations, health plans, associations and others to discuss the future of healthcare information technology and healthcare reform, and celebrate the contributions the organization has made to transforming the industry. For over 30 years, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v116/%3B%97g%FA%12%7Bzz NEW ORLEANS, May 17 /PRNewswire-FirstCall/ - Actelion Ltd announced today that findings from the REVEAL (Registry to EValuate Early And Long-term PAH Disease Management) Registry have confirmed the clinical utility of the REVEAL risk score calculator, a new tool designed to predict 1-year survival in patients with pulmonary arterial hypertension (PAH) according to data presented at the American Thoracic Society's (ATS) Annual International Conference. The predictive tool was developed and validated in patients enrolled in REVEAL, the largest prospective registry in PAH containing data from more than 3,500 patients. "The REVEAL risk score calculator provides an innovative approach to (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v116/%3B%97g%FA%12x%7Fx DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/79ddfd/gprotein_coupled) has announced the addition of the "G-Protein Coupled Receptors (GPCRs) - Global Strategic Business Report" report to their offering. G-Protein Coupled Receptors (GPCRs) - Global Strategic Business Report This report analyzes the Global market for G-Protein Coupled Receptors (GPCRs) in US$ Billion. Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 42 companies including 7TM Pharma A/S, Actelion Pharmaceuticals Ltd., Acure Pharma AB, Anchor Therapeutics, Arena (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v116/%3B%97g%FC%16%7F%7D%7E Sphingosine-1-phosphate (S1P) is a widespread lysophospholipid which displays a wealth of biological effects. Extracellular S1P conveys its activity through five specific G-protein coupled receptors numbered S1P(1) through S1P(5). Agonists of the S1P(1) receptor block the egress of T-lymphocytes from thymus and lymphoid organs and hold promise for the oral treatment of autoimmune disorders. Here, we report on the discovery and detailed structure-activity relationships of a novel class of S1P(1) receptor agonists based on the 2-imino-thiazolidin-4-one scaffold. Compound 8bo (ACT-128800) emerged from this series and is a potent, selective, and orally active S1P(1) receptor agonist selected (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v116/%3B%97g%FD%16z%7D%7E DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/c21086/licensing_opportun) has announced the addition of Decision Resources, Inc.'s new report "Licensing Opportunities: Neurology" to their offering. The future of drug discovery and development will be modeled on extensive cooperation and collaboration between multiple academic, government, non-profit, and industry stakeholders not on the individual R&D silos that pharmaceutical companies have instituted until very recently. Neurological drug discovery and development will benefit significantly from this new approach, given the intractable and complex nature of neurological diseases. Large and small (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v116/%3B%97%60%F9%13%7Dx%7C BACKGROUND: We aimed to investigate the extent of pharmacokinetic drug interactions between bosentan and a fixed combination of lopinavir/ritonavir. METHODS: This was a three-way crossover study in 12 healthy male participants treated with bosentan (125 mg twice daily) and lopinavir/ritonavir (400/100 mg twice daily) alone or in combination for 9.5 days. RESULTS: Combination treatment resulted in slightly lower area under the concentration-time curve during the 12 h dosing interval under steady-state conditions (AUC(tau,ss) values of both lopinavir and ritonavir with geometric mean ratios (GMRs; 90% confidence intervals [CIs]) of 0.86 (0.74-0.99) for lopinavir and 0.83 (0.76-0.92) for (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v116/%3B%97%60%FA%10u%7E%7C Almorexant, a dual orexin receptor antagonist potentially representing a new class of sleep-promoting compounds, was administered in an ascending single-dose study to evaluate tolerability, pharmacokinetics, and pharmacodynamics. Seventy healthy male subjects were enrolled in this double-blind, placebo- and active-controlled study. Each dose level (1-1,000 mg) was investigated in a separate group of 10 subjects (6 on almorexant, 2 on placebo, 2 on zolpidem 10 mg). Almorexant was well tolerated with no signs of cataplexy. Peak plasma concentration (C(max) was quickly attained (median time to maximum concentration (t(max) ranged from 0.7 to 2.3 h), and plasma concentrations subsequently (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v116/%3B%97%60%FD%1C%7Fx%7D Endothelins were first identified as potent vasoactive peptides; however, diversity in the biological function of these hormones is now evident. We have identified a novel role for endothelins: a requirement for these peptides within the oviduct during fertilization and/or early embryo development. In vivo, treatment after ovulation with a dual endothelin receptor antagonist (tezosentan) decreased the number of two-cell embryos that could be collected from within the oviducts. In vitro fertilization experiments showed that gamete viability and their ability to fertilize were not affected by treatment with this antagonist, suggesting that the effect observed in vivo was mediated by the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v116/%3B%97%60%FD%1C%7Cyy SOUTH SAN FRANCISCO, Calif. and MEMPHIS, Tenn., April 22 /PRNewswire/ - Actelion Pharmaceuticals US, Inc., today announced that it has selected Accredo Health Group, Inc., a wholly-owned subsidiary of Medco Health Solutions, Inc., to serve as the sole specialty pharmacy provider of Epoprostenol for Injection, the only epoprostenol formulated to provide up to 24-hour stability at room temperature without the use of ice packs. This improved formulation of Epoprostenol for Injection is commercially available today in the United States for the treatment of primary pulmonary hypertension and pulmonary hypertension associated with scleroderma spectrum of disease in NYHA Class III and IV (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v116/%3B%97%60%FD%1C%7C%7Bs SOUTH SAN FRANCISCO, Calif., April 22 /PRNewswire/ - Actelion Pharmaceuticals US, Inc. today announced the commercial availability of Epoprostenol for Injection, an improved formulation of epoprostenol that is stable at room temperature, for the treatment of primary pulmonary hypertension and pulmonary hypertension associated with scleroderma spectrum of disease in NYHA Class III and Class IV patients. Simultaneously, the company has launched the PROSPECT registry, a multicenter, observational, U.S.-based registry that will provide additional clinical experience on patients being treated with Epoprostenol for Injection. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v116/%3B%97%60%FF%14%7B%7Ey SINGAPORE-(BUSINESS WIRE)-Invida Group, the leading provider of healthcare brands and services to the Asia Pacific region, today announced that its contract with Swiss biotechnology company, Actelion, has been extended through 2015 to continue commercialization of Tracleer for the treatment of pulmonary arterial hypertension (PAH) in crucial markets throughout Asia. Actelion signed with Invida initially in 2005, and has extended the contract to market the companys lead product, Tracleer, in Thailand, Malaysia, Philippines, Vietnam, and Hong Kong By extending the contract, Invida will continue to leverage its experience in regulatory and medical affairs, specialized marketing, and its (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v116/%3B%97%60%FF%14z%7E%7C SINGAPORE-(BUSINESS WIRE)-Invida Group, the leading provider of healthcare brands and services to the Asia Pacific region, today announced that its contract with Swiss biotechnology company, Actelion, has been extended through 2015 to continue commercialization of Tracleer for the treatment of pulmonary arterial hypertension (PAH) in crucial markets throughout Asia. Actelion signed with Invida initially in 2005, and has extended the contract to market the company s lead product, Tracleer, in Thailand, Malaysia, Philippines, Vietnam, and Hong Kong. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v116/%3B%97%60%FF%14%7F%7Fy DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/6c4d91/idiopathic_pulmona) has announced the addition of GlobalData 's new report "Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2016" to their offering. Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2016 Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2016, is an essential source of information and analysis on the global idiopathic pulmonary fibrosis (IPF) market. The report identifies the key trends shaping and driving the global IPF market. The report also provides insight into the prevalent competitive (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v116/%3B%97%60%FF%15%7B%7Cx LAVAL, CANADA-(Marketwire - March 23, 2010) - Actelion Ltd (SIX:ATLN) announced the approval of a new indication for Zavesca (miglustat) in Canada; the first and only treatment available for people with Niemann-Pick type C (NP-C) disease [1]. NP-C is a rare, genetic disease with significant neurological deterioration that can be fatal and affects infants, children and adults [2,3]. Currently there is no cure for NP-C. Prior to Zavesca patient management was restricted to symptom relief [4]. Zavesca is indicated to slow the progression of some of the neurological manifestations in patients with Niemann-Pick Type C disease [1]. Neurological deterioration is the key feature of NP-C, which (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v116/%3B%97%60%FF%15%7B%7F%7B LAVAL, CANADA-(Marketwire - 23 mars 2010) - Actelion Ltd (SIX:ATLN) a annoncé l'approbation d'une nouvelle indication de Zavesca (miglustat) au Canada; le premier et le seul traitement autorisé pour les personnes atteintes de la maladie de Niemann-Pick de type C (NP-C) [1]. La maladie de NP-C est une maladie génétique rare associée à une importante détérioration neurologique potentiellement mortelle, qui touche les nourrissons, les enfants et les adultes [2, 3]. La maladie de NP-C est actuellement incurable. Avant l'arrivée de Zavesca, la prise en charge des patients était limitée au soulagement des symptà mes [4]. Zavesca est homologué pour ralentir (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v116/%3B%97a%F6%14%7F%7E%7B The urotensin system has been hypothesized to play an important role in the pathophysiology of diabetic nephropathy. In this multicenter, randomized, double-blind, placebo-controlled, 2-period crossover study, the effects of the urotensin receptor antagonist palosuran on urinary albumin excretion and blood pressure in hypertensive patients with type 2 diabetic nephropathy treated with a single blocker of the renin-angiotensin-aldosterone system were assessed. Patients with 24-hour albuminuria 0.5 and 135 and 85 and text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v116/%3B%97a%F7%10y%7D%7D Presse Med. |-| Gressin V. |-| Actelion Pharmaceuticals France, 75001 Paris, France. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v116/%3B%97a%F7%11%7C%7C%7B Presse Med. |-| Schwebig A. |-| Actelion Pharmaceuticals France SAS, 21, boulevard de la Madeleine (Hall E), 75001 Paris, France. text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v116/%3B%97a%F9%1Du%7Bx 10.03.2010 - Actelion Ltd announced that the company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for Zavesca (miglustat) for the treatment of progressive neurological manifestations in adult and pediatric patients with Niemann-Pick type C (NP-C) disease, a rare, neurodegenerative genetic disorder. The FDA has requested additional preclinical and clinical information. Actelion will work diligently with the FDA to explore the best ways to address the points raised by the agency. Jean-Paul Clozel, M.D. and Chief Executive Officer of Actelion commented: "We remain committed to bringing an approved (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v116/%3B%97a%F9%1D%7B%7C%7E NEW YORK, March 9 /PRNewswire/ - Reportlinker.com announces that a new market research report is available in its catalogue: Global Anti-Hypertensive Drugs Industry http:/www.reportlinker.com/p0181076/Global-Anti-Hypertensive-Drugs-Industry.html This report analyzes the worldwide markets for Anti-Hypertensive Drugs in US$ Million. The report provides separate comprehensive analytics for US, Europe and Rest of World. Annual forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 145 companies including many key and niche players worldwide such as AstraZeneca PLC, AstraZeneca PLC, Biovail (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v116/%3B%97a%F9%16u%7C%7E NEW YORK-(BUSINESS WIRE)-Omthera Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focusing on the clinical development of new dyslipidemia therapies, today announced commencement of operations in Bedminster, New Jersey. Omthera s lead product candidate, Epanova ¢, an Omega 3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), has shown promising results in lowering triglycerides in earlier clinical trials, as well as an excellent safety and tolerability profile. The Omthera management team includes drug development and commercialization expert Jerry Wisler, president and chief executive officer, and cardiologist and (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v116/%3B%97a%FA%12%7E%7F%7F NEW YORK, March 4 /PRNewswire/ - Reportlinker.com announces that a new market research report is available in its catalogue: Opportunities in Orphan Drugs: Strategies for developing maximum returns from niche indications http:/www.reportlinker.com/p0180554/Opportunities-in-Orphan-Drugs-Strategies-for-developing-maximum-returns-from-niche-indications.html The US government introduced the Orphan Drugs Act (ODA) in 1983 as a means to provide incentives to drug developers so that they would develop treatments for diseases for which incidence is so low that that normal market forces are unable to deliver effective medication for these conditions. A 1984 modification to the ODA defined an (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v116/%3B%97a%FA%13uv%7F DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/1d3bbf/opportunities_in_o) has announced the addition of the "Opportunities in Orphan Drugs: Strategies for Developing Maximum Returns from Niche Indications" report to their offering. Opportunities in Orphan Drugs: Strategies for Developing Maximum Returns from Niche Indications The US government introduced the Orphan Drugs Act (ODA) in 1983 as a means to provide incentives to drug developers so that they would develop treatments for diseases for which incidence is so low that normal market forces are unable to deliver effective medication for these conditions. A 1984 modification to the ODA defined (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v116/%3B%97a%FA%13u%7C%7F DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/6f78ea/pulmonary_arterial) has announced the addition of GlobalData's new report "Pulmonary Arterial Hypertension (PAH) - Drug Pipeline Analysis and Market Forecasts to 2016" to their offering. Pulmonary Arterial Hypertension (PAH) - Drug Pipeline Analysis and Market Forecasts to 2016 Pulmonary Arterial Hypertension (PAH) - Drug Pipeline Analysis and Market Forecasts to 2016 GlobalData, the industry analysis specialist, has released its latest research, Pulmonary Arterial Hypertension (PAH) - Drug Pipeline Analysis and Market Forecasts to 2016, which provides key data, information and analysis on the (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v116/%3B%97a%FB%11%7Fy%7B 02.03.2010 - Actelion Ltd announced the initial results of BUILD-3, a clinical study evaluating the safety and efficacy of bosentan in patients suffering from idiopathic pulmonary fibrosis. While there was a consistent trend in favor of bosentan, the primary endpoint, reduction in morbidity/mortality, was not met (p=0.21). The well characterized safety profile of bosentan was confirmed. Jean-Paul Clozel, M.D. and Chief Executive Officer of Actelion commented: "We are naturally disappointed with this outcome. While in BUILD-3 there is a consistent trend in favor of bosentan, these findings do not support initiating regulatory proceedings." Jean-Paul Clozel continued: "We remain convinced (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v116/%3B%97a%FB%16yz%7C 01.03.2010 - Top pharmaceutical and biotech companies face a major slow down in sales growth over 2008–14 according to a new report by independent business analyst Datamonitor. The report title "Pharmaceutical Company Outlook to 2014 considers the forecast performance of the world s biggest pharmaceutical (Pharma) and biotech companies, termed the "PharmaVitae Universe . The analysis reveals prescription sales are expected to rise at a compound annual growth rate (CAGR) of 1.2% out to 2014, compared to a historical growth rate of 10.5% over 2002–08. The sharp decline in industry growth rate is primarily a result of the generic competition facing many companies, with several blockbuster (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v116/%3B%97a%FC%12yx%7C Importance of the field: The orexin neuropeptide system plays a central role in maintaining arousal and wakefulness. It has been demonstrated that small molecule antagonists to the orexin receptors promote sleep in preclinical species and in patients with insomnia. Areas covered in this review: This review provides a summary of published patent applications claiming novel orexin antagonists from 2006 to mid-2009, covering both selective and dual orexin receptor antagonists. What the reader will gain: Readers will gain an overview of orexin biology focusing on genetic and pharmacological validation of this target for treating sleep disorders. Additionally, this review discusses the (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v116/%3B%97a%FC%16xx%7D NEW YORK, Feb. 24 /PRNewswire/ - Guidepoint Global, LLC, a leading primary research firm, today announced the launch of their Genetic Disorder Tracker, a monthly longitudinal data release that captures commercial trends, on a worldwide basis, associated with the treatment of eight rare genetic disorders: Gaucher's disease, Fabry's disease, PKU, MPS I (Hurler Syndrome), MPS II (Hunter Syndrome), MPS VI (Maroteaux-Lamy Syndrome), Niemann-Pick disease and Pompe disease. Guidepoint's Genetic Disorder Tracker aggregates the utilization of more than 10 therapies reported by a clinical sample comprised of more than 100 worldwide sites in over 20 countries. Key commercial metrics covered by the (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v116/%3B%97a%FC%15x%7Cr ROCKVILLE, MD-(Marketwire - February 23, 2010) - MarketResearch.com has announced the addition of GBI Research's new report "The Future of Orphan Disease Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement," to their collection of Drug Discovery market reports. For more information, visit http:/www.marketresearch.com/redirect.asp?progid=67618&productid=2529138. GBI Research, the leading business intelligence provider, has released its latest research "The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement." The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global orphan (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v116/%3B%97a%FE%12u%7Fs NEW YORK, Feb. 18 /PRNewswire/ - Reportlinker.com announces that a new market research report is available in its catalogue: Opportunities in Orphan Drugs: Strategies for developing maximum returns from niche indications http:/www.reportlinker.com/p0177851/Opportunities-in-Orphan-Drugs-Strategies-for-developing-maximum-returns-from-niche-indications.html The US government introduced the Orphan Drugs Act (ODA) in 1983 as a means to provide incentives to drug developers so that they would develop treatments for diseases for which incidence is so low that that normal market forces are unable to deliver effective medication for these conditions. A 1984 modification to the ODA defined an (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v116/%3B%97a%FF%1Ctvs DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/25703c/top_10_biotech_com) has announced the addition of the "Top 10 Biotech Companies: Media Monitor" newsfeed to their offering. Companies monitored: Amgen Genentech UCB Gilead Sciences Genzyme Biogen Idec CSL Cephalon Celgene Actelion About the service: When biotechnology company news breaks, we get it fast so you can deliver fresh business intelligence. Search 33,500 news sources Plus, search 508,000 social media sources Covers 200 countries 50 languages Our proprietary indexing technology and ability to simultaneously monitor and collate from our sources means that we take care of the hard work (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v116/%3B%97a%FF%17%7Ewx LONDON-(BUSINESS WIRE)-ChEMBLdb, an online database of information on the properties of more than half a million drug and drug-like small molecules and their targets, has been launched. Hosted by the European Molecular Biology Laboratory's European Bioinformatics Institute (EMBL-EBI), this unique resource brings together information from the interface of the genome with chemistry into a set of 'chemogenomic' databases that can be used to help determine whether a particular molecule has the right properties to make an effective drug. At the same time, an integrated resource for sequence, compound and screening data from a variety of sources for the protein kinases has been released. As (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v116/%3B%97b%F6%13u%7Ez A novel series of dual orexin receptor antagonists was prepared by heteroaromatic five-membered ring system replacement of the dimethoxyphenyl moiety contained in the tetrahydroisoquinoline core skeleton of almorexant. Thus, replacement of the dimethoxyphenyl by a substituted pyrazole and additional optimization of the substitution pattern of the phenethyl motif allowed the identification of potent antagonists with low nanomolar affinity for hOX(1)R and hOX(2)R. The synthesis and structure-activity relationship of these novel antagonists will be discussed in this communication. These investigations furnished several suitable candidates for further evaluation in in vivo studies in rats. |-| (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v116/%3B%97b%FE%17txr 15.01.2010 - Actelion Ltd announced that United States (US) Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted (10 yes to 3 no) in its final vote in question that the benefit/risk profile of Zavesca (miglustat) supports its approval for the treatment of progressive neurological manifestations in adult patients and pediatric patients with Niemann-Pick type C (NP-C) disease. The decision was based on results from the clinical trial OGT 918-007 and two multicenter NP-C disease cohort studies as well as other clinical trials in related lysosomal storage disorders for the safety and tolerability evaluation. Jean-Paul Clozel, M.D. and Chief (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v116/%3B%97b%FE%14t%7Bs Reuters - A U.S. advisory panel on Tuesday recommended approval of an Actelion Ltd drug for treating a rare disease that often kills patients in their teens after fats accumulate in their organs. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v116/%3B%97c%F7%14%7Ey%7B ABSTRACT Background: The Bosentan Patient Registry (BPR) was a prospective, multicentre, Australian registry funded by Actelion Pharmaceuticals. The primary aim of the registry was to collect survival data in patients with pulmonary arterial hypertension (PAH) treated with bosentan. Methods: The BPR was initiated in 15 specialised PAH centres. All patients on or starting bosentan were invited to enrol. Treating physicians notified the registry if patients discontinued bosentan, either due to a change in therapy, transplantation, intervention or death. Survival data were validated against the Australian Institute of Health and Welfare National Death Index. Results: Between 2004 and 2007, a (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v116/%3B%97c%F9%15xzx Almorexant (ACT-078573) is an orally active dual orexin receptor antagonist that is being developed by Actelion Ltd, in collaboration with GlaxoSmithKline plc, for the treatment of primary insomnia. Almorexant is a first-in-class compound that targets the orexin system, which plays a key role in wake promotion and stabilization, in addition to having other regulatory functions. Decreasing orexin activity was hypothesized to have a sleep-promoting effect. Preclinical studies and phase I clinical trials have demonstrated that almorexant decreases alertness and increases sleep in healthy rats, dogs and humans when administered during the active phase of the circadian cycle, at peak endogenous (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v116/%3B%97c%FC%12ux%7B Reuters - Questions about effectiveness are the main issue surrounding Actelion Ltd's (ATLN.VX) bid to sell a drug for treating a rare disease affecting the brain, U.S. drug reviewers said in documents released on Friday. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v116/%3B%97c%FD%1Dx%7Bz The involvement of transport proteins in the disposition of drugs is receiving much attention of the scientific community. Recently, researchers from academia have surmised that drug transport rather than passive diffusion is the regular mechanism for molecules to cross cell membranes. On bare face value, however, sound evidence of the impact of transport proteins on clinical pharmacokinetics has been a trickle rather than a stream of convincing studies during the last decade, in stark contrast to the number of in vitro studies published. Progress in this area may have been impeded by a number of factors. Only a limited number of small-molecule drugs fall within the physicochemical (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v116/%3B%96j%F6%14yys LEIDEN, The Netherlands, November 17 /PRNewswire/ - Top Institute Pharma (TI Pharma) has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke. Based on novel action mechanisms, new drugs may be discovered with the potential to prevent vascular complications in patients with hypertension: an opportunity to improve the quality of life for over a billion people worldwide. This collaboration, involving 3.4 million euros, 9 new research positions, unique (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v116/%3B%96j%FA%15x%7Cr DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/17c3a0/the_future_of_orph) has announced the addition of the "The Future of Orphan Disease Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement" report to their offering. The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement "The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement" The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global orphan diseases therapeutics market. The report analyzes the markets for orphan diseases (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v116/%3B%96j%FB%1C%7Dv%7C NEW YORK, Dec. 15 /PRNewswire/ - Reportlinker.com announces that a new market research report is available in its catalogue: The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement http:/www.reportlinker.com/p0168104/The-Future-of-Orphan-Diseases-Therapeutics-Market-Forecasts-to-2015-Pipeline-Analysis-and-Reimbursement.html Summary The author has released its latest research "The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement" The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global orphan diseases therapeutics market. The report analyzes (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v116/%3B%96j%FB%12tvs WASHINGTON-(BUSINESS WIRE)-The Biotechnology Industry Organization (BIO) today announced the first 100 companies selected to present at the Twelfth Annual BIO CEO & Investor Conference. Presenting companies were selected through a rigorous screening process and were evaluated based on several criteria, including their potential to deliver on near-term clinical catalysts and accomplishments across major therapeutic markets and areas of unmet medical need. The BIO CEO & Investor Conference will showcase companies representing the industrys most promising investment opportunities with late-stage clinical pipelines, well-established business strategies or strong M&A and partnering potential (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v116/%3B%96j%FB%10zvs 23.12.2009 - Actelion Ltd announced that the first phase III study with almorexant (RESTORA 1) has met its primary endpoint, superiority of the dual orexin receptor antagonist almorexant compared to placebo on objective and subjective wake after sleep onset (WASO). The finding was highly significant (p text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v116/%3B%96j%FB%10xws Reuters - Actelion, Europe's largest biotech company, forecast an $80 million hit to 2009 operating profit after an arbitration panel ruled against a unit in a dispute with a Japanese drug firm. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v116/%3B%96j%FB%10%7E%7E%7D Dow Jones - Swiss biotech company Actelion Ltd. said Monday its experimental sleeping pill almorexant met its main target in a two week late-stage trial, but noted that certain "safety observations" were made that need to be analyzed further, raising concerns over the drug's long-term potential.